Gevokizumab

DB12119InvestigationalProtein Based Therapies

Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine... It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

Mechanism: Pharmacologically active on Interleukin-1 beta
Curator reviewed
Code names: XOMA 052

Resolves to

Compound

UNIIQX3JU54GYQCAS1129435-60-4

Targets

P01584IL1B

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gevokizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account